Home › Cancro metastatico › Michigan › Detroit
Studi clinici su Cancro metastatico a Detroit, MI
24 studi su Cancro metastatico cercano partecipanti presso sedi a Detroit e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
In reclutamentoFase 2/3
- Henry Ford Cancer- Detroit, Detroit
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
In reclutamentoFase 3
- Research Site, Detroit
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
In reclutamentoFase 1/2
- Henry Ford Cancer Institute, Detroit
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
In reclutamentoFase 1
- Karmanos Cancer Institute, Detroit
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
In reclutamentoFase 1
- Barbara Ann Karmanos Cancer Institute, Detroit
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
In reclutamentoFase 3
- Karmanos Cancer Institute, Detroit
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
In reclutamentoFase 3
- Karmanos Cancer Institute, Detroit
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
In reclutamentoFase 1/2
- Clinical Study Site, Detroit
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
In reclutamentoFase 2
- Henry Ford Cancer Institute/Henry Ford Health System, Detroit
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
In reclutamentoFase 1
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
In reclutamentoFase 1/2
- Crinetics Study Site, Detroit
A Study of ASP1002 in Adults for Treatment of Solid Tumors
In reclutamentoFase 1
- Henry Ford Hospital, Detroit
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
In reclutamentoFase 1
- Investigative Site #120, Detroit
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
In reclutamentoFase 1
- Henry Ford Health System, Detroit
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
In reclutamentoFase 1/2
- Henry Ford Hospital, Detroit
Laser Interstitial Thermal Ablation and Stereotactic Radiosurgery for Patients With Spine Metastases
In reclutamento
- Henry Ford Hospital, Detroit
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
In reclutamentoFase 1/2
- Henry Ford Cancer Institute, Detroit
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
In reclutamentoFase 3
- Henry Ford Health System, Detroit
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
In reclutamentoFase 1/2
- Karmanos Cancer Institute, Detroit
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
In reclutamentoFase 1/2
- Karmanos Cancer Institute, Detroit
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
In reclutamentoFase 1
- Henry Ford Cancer Center, Detroit
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
In reclutamentoFase 1
- Henry Ford Cancer Institute, Detroit
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
In reclutamentoFase 1
- Karmanos Cancer Institute, Detroit
A Beta-only IL-2 ImmunoTherapY Study
In reclutamentoFase 1/2
- Karmanos Cancer Institute, Detroit
Studi su Cancro metastatico in altre città
- Houston, TX104 studi
- New York City, NY93 studi
- Nashville, TN70 studi
- Boston, MA63 studi
- Los Angeles, CA57 studi
- St. Louis, MO54 studi
- Arlington, VA53 studi
- Philadelphia, PA46 studi
- Chicago, IL45 studi
- San Antonio, TX44 studi
- Washington, DC43 studi
- Dallas, TX42 studi
Altri studi a Detroit
- Cancro del polmone non a piccole cellule44 studi
- Cancro al seno33 studi
- Cancro (tutti i tipi)29 studi
- Cancro colorettale26 studi
- Cancro ovarico26 studi
- Cancro alla prostata22 studi
- Cancro dell'endometrio21 studi
- Cancro ai polmoni20 studi
- Mieloma multiplo19 studi
- Cancro dello stomaco16 studi
- Carcinoma a cellule squamose della testa e del collo15 studi
- Leucemia mieloide acuta14 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.